{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:34:34Z","timestamp":1792218874096,"version":"4.4.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"IBD Disease Specific Programme"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Understanding disease burden is imperative for improving inflammatory bowel disease (IBD) management. This real-world survey investigated residual disease burden and treatment satisfaction among European patients with moderate-to-severe ulcerative colitis (UC) and Crohn\u2019s disease (CD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Adelphi Real World IBD Disease Specific Programme was a multinational, cross-sectional survey with retrospective collection of patient- and physician-reported data on disease burden and management. Between October 2020 and March 2021, participating gastroenterologists recruited their next 7 (UC) and 8 (CD) eligible patients and reported demographics and clinical characteristics. Patients completed symptom, health-related quality of life (HRQoL), and treatment satisfaction questionnaires. Data were adjusted for confounding variables and compared between patients in remission (clinical remission, endoscopic remission, or both) and not in remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1040 patients (UC, n\u2005=\u2005502; CD, n\u2005=\u2005538) were included. Although most patients were in remission (UC, 66.1%; CD, 69.5%), most still reported symptoms (UC, 63.7%; CD, 74.1%), including flatulence, fatigue\/tiredness, and abdominal pain\/distension. In UC, there were no significant differences in the likelihood of experiencing 7 of 23 symptoms between patients in remission and not in remission. In CD, there was no significant difference in 19 of 23 symptoms between patients in remission and not in remission. Several symptoms were significantly associated with reduced HRQoL. HRQoL was significantly better among patients in remission than not in remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with IBD, both in remission and not in remission, experience residual symptoms that impair HRQoL. Comprehensive endpoints, incorporating HRQoL and patients\u2019 perspectives, and improved treatments are needed to address residual disease and patients\u2019 needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izae119","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:15:08Z","timestamp":1715242508000},"page":"411-424","source":"Crossref","is-referenced-by-count":18,"title":["Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-5139","authenticated-orcid":false,"given":"Johan","family":"Burisch","sequence":"first","affiliation":[{"name":"Gastrounit, Medical Division, Copenhagen University Hospital \u2013 Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Copenhagen University Hospital \u2013 Amager and Hvidovre , Hvidovre ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7141-6076","authenticated-orcid":false,"given":"Ailsa","family":"Hart","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, St Mark\u2019s Hospital , Harrow ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8759-7342","authenticated-orcid":false,"given":"Andreas","family":"Sturm","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine - Gastroenterology, German Red Cross Hospital Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7678-6519","authenticated-orcid":false,"given":"Christine","family":"Rudolph","sequence":"additional","affiliation":[{"name":"Galapagos NV , Leiden ,","place":["Netherlands"]},{"name":"Employee of Alfasigma S.p.A at the time of publication"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9047-4733","authenticated-orcid":false,"given":"Rachael","family":"Meadows","sequence":"additional","affiliation":[{"name":"Adelphi Real World , Bollington ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8610-8288","authenticated-orcid":false,"given":"Anna","family":"Jus","sequence":"additional","affiliation":[{"name":"Galapagos NV , Leiden ,","place":["Netherlands"]},{"name":"Employee of Alfasigma S.p.A at the time of publication"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-6862","authenticated-orcid":false,"given":"Fatima","family":"Dawod","sequence":"additional","affiliation":[{"name":"Adelphi Real World , Bollington ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-5163","authenticated-orcid":false,"given":"Haridarshan","family":"Patel","sequence":"additional","affiliation":[{"name":"Galapagos NV , Mechelen ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-0118","authenticated-orcid":false,"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Diseases Center, IRCCS Humanitas Research Hospital , Rozzano ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"issue":"1","key":"2025021012301369500_CIT0001","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12876-019-0963-7","article-title":"Presenting symptoms in inflammatory bowel disease: descriptive analysis of a community-based inception cohort","volume":"19","author":"Perler","year":"2019","journal-title":"BMC Gastroenterol."},{"issue":"4","key":"2025021012301369500_CIT0002","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000496739","article-title":"Unmet medical needs in ulcerative colitis: an expert group consensus","volume":"37","author":"Danese","year":"2019","journal-title":"Dig Dis."},{"issue":"10","key":"2025021012301369500_CIT0003","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.crohns.2014.03.005","article-title":"IBD and health-related quality of life -- discovering the true impact","volume":"8","author":"Lonnfors","year":"2014","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2025021012301369500_CIT0004","doi-asserted-by":"crossref","first-page":"e0197351","DOI":"10.1371\/journal.pone.0197351","article-title":"Patient-reported healthcare expectations in inflammatory bowel diseases","volume":"13","author":"Pittet","year":"2018","journal-title":"PLoS One."},{"issue":"7","key":"2025021012301369500_CIT0005","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.dld.2021.03.002","article-title":"Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review","volume":"53","author":"Armuzzi","year":"2021","journal-title":"Dig Liver Dis."},{"issue":"13","key":"2025021012301369500_CIT0006","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.3390\/ijerph18137159","article-title":"Role of quality of life as endpoint for inflammatory bowel disease treatment","volume":"18","author":"Calvino-Suarez","year":"2021","journal-title":"Int J Environ Res Public Health."},{"issue":"2","key":"2025021012301369500_CIT0007","doi-asserted-by":"publisher","first-page":"179","DOI":"10.14309\/ajg.0000000000000437","article-title":"Histological remission in ulcerative colitis: under the microscope is the cure","volume":"115","author":"Chateau","year":"2020","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"2025021012301369500_CIT0008","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000527846","article-title":"Positioning and usefulness of biomarkers in inflammatory bowel disease","volume":"104","author":"Sakurai","year":"2023","journal-title":"Digestion."},{"issue":"5","key":"2025021012301369500_CIT0009","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"key":"2025021012301369500_CIT0010","doi-asserted-by":"publisher","first-page":"765474","DOI":"10.3389\/fmed.2021.765474","article-title":"Treatment of inflammatory bowel disease: a comprehensive review","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025021012301369500_CIT0011","doi-asserted-by":"publisher","first-page":"212572","DOI":"10.7573\/dic.212572","article-title":"New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance","volume":"8","author":"Tripathi","year":"2019","journal-title":"Drugs Context"},{"issue":"5","key":"2025021012301369500_CIT0012","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/03007995.2023.2194782","article-title":"The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom","volume":"39","author":"Lindsay","year":"2023","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"2025021012301369500_CIT0013","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00384-023-04397-7","article-title":"Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany","volume":"38","author":"Bokemeyer","year":"2023","journal-title":"Int J Colorectal Dis."},{"issue":"2","key":"2025021012301369500_CIT0014","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/1756283X09102329","article-title":"Ulcerative colitis: current treatment strategies and future prospects","volume":"2","author":"Garud","year":"2009","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"2025021012301369500_CIT0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/ecco-jcc\/jjx152","article-title":"Irritable bowel-like symptoms in ulcerative volitis are as common in patients in deep remission as in inflammation: results from a population-based study [the IBSEN Study]","volume":"12","author":"Henriksen","year":"2018","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2025021012301369500_CIT0016","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2025021012301369500_CIT0017","doi-asserted-by":"publisher","first-page":"otaa033","DOI":"10.1093\/crocol\/otaa033","article-title":"Patient\u2019s perspective on disease burden, remission definition, and symptoms associated with treatment seeking: a qualitative study in adult and adolescent patients with Crohn\u2019s disease","volume":"2","author":"Kitchen","year":"2020","journal-title":"Crohns Colitis 360"},{"issue":"1","key":"2025021012301369500_CIT0018","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12876-020-1164-0","article-title":"The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe","volume":"20","author":"Armuzzi","year":"2020","journal-title":"BMC Gastroenterol."},{"issue":"3","key":"2025021012301369500_CIT0019","doi-asserted-by":"publisher","first-page":"otac023","DOI":"10.1093\/crocol\/otac023","article-title":"Work-related productivity loss and associated indirect costs in patients with Crohn\u2019s disease or ulcerative colitis in the United States","volume":"4","author":"Ding","year":"2022","journal-title":"Crohns Colitis 360."},{"issue":"2","key":"2025021012301369500_CIT0020","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s12325-022-02364-2","article-title":"Burden of fatigue among patients with ulcerative colitis and Crohn\u2019s disease: results from a global survey of patients and gastroenterologists","volume":"40","author":"Regueiro","year":"2023","journal-title":"Adv Ther."},{"issue":"1","key":"2025021012301369500_CIT0021","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12876-023-02640-7","article-title":"Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries","volume":"23","author":"Armuzzi","year":"2023","journal-title":"BMC Gastroenterol."},{"issue":"11","key":"2025021012301369500_CIT0022","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin."},{"issue":"8","key":"2025021012301369500_CIT0023","doi-asserted-by":"publisher","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","article-title":"Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme","volume":"6","author":"Babineaux","year":"2016","journal-title":"BMJ Open"},{"key":"2025021012301369500_CIT0024","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025021012301369500_CIT0025","author":"EPHMRA","year":"2022"},{"key":"2025021012301369500_CIT0026","year":"2009"},{"issue":"3","key":"2025021012301369500_CIT0027","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol","year":"1990","journal-title":"Health Policy"},{"issue":"8","key":"2025021012301369500_CIT0028","first-page":"1571","article-title":"The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn\u2019s Relapse Prevention Trial","volume":"91","author":"Irvine","year":"1996","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2025021012301369500_CIT0029","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics."},{"issue":"1","key":"2025021012301369500_CIT0030","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000494412","article-title":"Irritable bowel syndrome-like symptoms in ulcerative colitis patients in clinical remission: association with residual colonic inflammation","volume":"99","author":"Ishihara","year":"2019","journal-title":"Digestion."},{"issue":"1","key":"2025021012301369500_CIT0031","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/jcm10010031","article-title":"IBS-symptoms in IBD patients-manifestation of concomitant or different entities","volume":"10","author":"Szalwinska","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"2025021012301369500_CIT0032","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12016-017-8641-4","article-title":"Unmet needs in IBD: the case of fatigue","volume":"55","author":"Hindryckx","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"issue":"4","key":"2025021012301369500_CIT0033","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41575-018-0091-9","article-title":"Fatigue in IBD: epidemiology, pathophysiology and management","volume":"16","author":"Borren","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"Suppl 1","key":"2025021012301369500_CIT0034","doi-asserted-by":"publisher","first-page":"A176","DOI":"10.1136\/gutjnl-2013-304907.399","article-title":"PWE-111 Assessment and implications of health-related quality of life in a district general cohort of inflammatory bowel disease patients","volume":"62","author":"Swart","year":"2013","journal-title":"Gut."},{"issue":"5","key":"2025021012301369500_CIT0035","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s11136-015-1164-7","article-title":"Normative values of EQ-5D-5L: in a Spanish representative population sample from Spanish Health Survey, 2011","volume":"25","author":"Garcia-Gordillo","year":"2016","journal-title":"Qual Life Res."},{"issue":"9","key":"2025021012301369500_CIT0036","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s11136-018-1877-5","article-title":"Validity of the EQ-5D-5L and reference norms for the Spanish population","volume":"27","author":"Hernandez","year":"2018","journal-title":"Qual Life Res."},{"issue":"3","key":"2025021012301369500_CIT0037","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/ijerph13030343","article-title":"EQ-5D-5L in the general German population: comparison and evaluation of three yearly cross-section surveys","volume":"13","author":"Huber","year":"2016","journal-title":"Int J Environ Res Public Health."},{"issue":"6","key":"2025021012301369500_CIT0038","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/ecco-jcc\/jjad018","article-title":"Filgotinib improved health-related quality of life and led to comprehensive disease control in individuals with ulcerative colitis: data from the SELECTION trial","volume":"17","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2025021012301369500_CIT0039","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ecco-jcc\/jjad130","article-title":"Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: international Delphi consensus recommendations","volume":"18","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2025021012301369500_CIT0040","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.crohns.2012.07.012","article-title":"Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors","volume":"7","author":"Moradkhani","year":"2013","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2025021012301369500_CIT0041","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000495293","article-title":"Accommodations and adaptations to overcome workplace disability in inflammatory bowel disease patients: a systematic review","volume":"3","author":"Paulides","year":"2019","journal-title":"Inflamm Intest Dis"},{"issue":"5","key":"2025021012301369500_CIT0042","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S2468-1253(21)00014-5","article-title":"Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"6","author":"Barberio","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"2025021012301369500_CIT0043","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41575-022-00634-6","article-title":"Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment","volume":"19","author":"Bisgaard","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae119\/58166945\/izae119.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/2\/411\/58166945\/izae119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/2\/411\/58166945\/izae119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T07:38:03Z","timestamp":1739173083000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/2\/411\/7689664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6,7]]},"published-print":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae119","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,6,7]]}}}